Cargando…
In Vitro Antibacterial Activity of Imipenem/Relebactam against Clinical Isolates in Japan
Relebactam is a novel β-lactamase inhibitor of Ambler class A and C β-lactamases that has been developed in combination with imipenem/cilastatin for the treatment of carbapenem-resistant bacterial infections. In this study, we evaluated the in vitro antibacterial activity of imipenem/relebactam (IMR...
| Autores principales: | , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
American Society for Microbiology
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9045147/ https://www.ncbi.nlm.nih.gov/pubmed/35416695 http://dx.doi.org/10.1128/spectrum.02235-21 |